IRWD
NASDAQIronwood Pharmaceuticals Inc.
Price$3.23-0.03 (-1.07%)
01:30 PM07:45 PM
News · 26 weeks41-33%
2025-12-072026-05-31
Mix2490d
- Insider8(33%)
- SEC Filings7(29%)
- Other7(29%)
- Earnings2(8%)
Latest news
25 items- PRIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide,
- PRFDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS remains the first-and-only FDA-approved prescription therapy for pediatric FC – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC.
- SECAmendment: Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- INSIDERPFO & PAO Silver Ronald was granted 25,000 shares, increasing direct ownership by 6% to 441,570 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
- SECIronwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- SECSEC Form 10-Q filed by Ironwood Pharmaceuticals Inc.10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- SECIronwood Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- PRIronwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – – Total revenue of $107 million, GAAP net income of $41 million and adjusted EBITDA of $77 million in Q1 2026 – – On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026 – – sNDA for LINZESS treatment of functional constipation (FC) in patients 2 to 5 years of age accepted and granted priority review by FDA; PDUFA date set for May 24th – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and com
- PRIronwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)– Surveyed HCPs identified reduction of days on TPN as a top priority – – Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence – – Additional presentations feature long-term apraglutide safety and tolerability data, new linaclotide data analyses across patient populations – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented new findings at Digestive Diseases Week® (DDW) 2026 from a survey assessing healthcare provider (HCP) perspectives on the use of total parenteral nutrition (T
- PRIronwood Pharmaceuticals to Host First Quarter 2026 Investor Update CallIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, May 7, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, May 21, 2026. To listen
- SECSEC Form DEFA14A filed by Ironwood Pharmaceuticals Inc.DEFA14A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- SECSEC Form DEF 14A filed by Ironwood Pharmaceuticals Inc.DEF 14A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
- PRIronwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are dependent on parenteral support (PS) – – Linaclotide data presentations highlight efficacy and safety insights in IBS-C, CIC and pediatric FC – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professiona
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
- INSIDERDirector Denner Alexander J was granted 4,451 shares and sold $20,530,448 worth of shares (6,730,800 units at $3.05), increasing direct ownership by 2% to 256,309 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERChief Legal Officer John Minardo was granted 136,612 shares, increasing direct ownership by 38% to 500,498 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERChief Financial Officer Martini Gregory S. was granted 136,612 shares, increasing direct ownership by 85% to 297,213 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERSVP, CMO, Head-Res&Drug Shetzline Michael was granted 136,612 shares, increasing direct ownership by 26% to 658,037 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERPrincipal Accounting Officer Silver Ronald was granted 163,934 shares, increasing direct ownership by 65% to 416,570 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERChief Commercial Officer Gaskins Tammi L was granted 136,612 shares, increasing direct ownership by 64% to 350,350 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERChief Executive Officer Mccourt Thomas A was granted 409,836 shares, increasing direct ownership by 28% to 1,898,838 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- SECIronwood Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- PRIronwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a ne
IRWD FAQ
7 questionsWhat does Ironwood Pharmaceuticals Inc. do?
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions...Where does IRWD stock trade?
Ironwood Pharmaceuticals Inc. (IRWD) is listed on NASDAQ.What sector and industry is IRWD in?
Ironwood Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ironwood Pharmaceuticals Inc. go public?
Ironwood Pharmaceuticals Inc. (IRWD) completed its IPO in 2010.What are analysts saying about IRWD?
Ironwood Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Outperform with a $800.00 price target on 2026-01-05.What companies are similar to IRWD?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IRWD side-by-side with any of them on Quantisnow.How can I track IRWD on Quantisnow?
Quantisnow aggregates Ironwood Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRWD to receive live email and push alerts on every new disclosure.